CN103695497A - Enzymatic preparation of naloxone and pharmaceutical composition thereof - Google Patents
Enzymatic preparation of naloxone and pharmaceutical composition thereof Download PDFInfo
- Publication number
- CN103695497A CN103695497A CN201310711466.8A CN201310711466A CN103695497A CN 103695497 A CN103695497 A CN 103695497A CN 201310711466 A CN201310711466 A CN 201310711466A CN 103695497 A CN103695497 A CN 103695497A
- Authority
- CN
- China
- Prior art keywords
- hydroxyl
- naloxone
- composition
- dihydrocodeinone
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a method for enzymatic preparation of naloxone. The enzyme is mild in reaction condition and free of harm to a human body. In addition, the invention also provides a naloxone composition prepared by the method and application thereof. The composition contains 14-hydroxy-7,8-dihydro codein ketone impurities, but the medicine performance can not be affected. Furthermore, the invention also provides an identification method of the naloxone composition and enzyme and the like for preparation.
Description
Technical field
The invention belongs to medical technical field, particularly, the present invention relates to naloxone composition prepared by enzyme process, although contain impurity, do not affect its patent medicine performance.
Background technology
Naloxone, chemical name is 17-allyl group-4,5a-epoxy group(ing)-3,14-dihydroxyl morphinan-6-ones, conventionally with the form patent medicine of hydrochloride, be the antagonist of opiate receptor, be mainly used in reversing the narcoticness analgesia and the respiration inhibition that due to morphine class material (drugs), cause, and can be used for saving that the materials such as ethanol cause is poisoning etc.
In recent years, to the research of naloxone be mainly conceived to its pharmaceutical preparation and with the coupling of other medicines on, as referring to Chinese patent (application) 03807796.5,200680005969.1,200510080479.5,201180023192.2,200880006847.3 etc.In addition, Chinese patent (application) 200710039118.5 and 201010211706.4 relates to the technology of preparing of naloxone and intermediate thereof, but still adopt chemical synthesising technology, since jumping out the eighties, do not utilized Hydrogen bromide or chloroformic acid etc. to carry out synthetic framework, , take thebaine as raw material, oxidation hydrogenation produces 14-hydroxyl-7, 8-dihydrocodeinone, then pass through complicated process, adding under the condition of protecting group, utilize the reagent such as Hydrogen bromide or chloroformic acid to carry out demethylation, then deprotection base, finally by alkylation, generate naloxone, wherein reaction (especially demethylation process) condition is violent, reagent and residual large to harm.
The inventor has finally obtained a kind of demethylase that can identify three-dimensional condensed ring system, can be by 14-hydroxyl-7 under mild conditions, and 8-dihydrocodeinone changes into 14-hydroxyl-7,8-dihydro desmethylmorphine ketone, thus can directly through alkylation, generate naloxone.In addition, remove 14-hydroxyl-7 of co-precipitation/crystallization, 8-dihydrocodeinone impurity can bring greater loss, and the inventor studies discovery, if removal of contamination and direct alkylation do not generate naloxone, the naloxone purity obtaining is still greater than 97%, meet medicinal requirements, and 14-hydroxyl-7 wherein, 8-dihydrocodeinone impurity does not form impact to its direct patent medicine, thereby can further reduce bulk drug cost as medicine.
Summary of the invention
The technical problem to be solved in the present invention is the method for preparing naloxone that provides new, and the enzyme that has wherein used prior art not point out makes enzyme reaction mild condition, harmless to human body basic.In addition, the present invention also provides naloxone composition and the application thereof being prepared by the method, although contain impurity in said composition, does not affect its patent medicine performance.Also have, the present invention also provides enzyme used in the authentication method of naloxone composition and preparation etc.
Particularly, in first aspect, the invention provides the method that enzyme process is prepared naloxone, it comprises,
(A) optionally thebaine hydrogen oxide is changed into 14-hydroxyl-7,8-dihydrocodeinone;
(B) under the effect of demethylase, by 14-hydroxyl-7,8-paracodin ketogenesis 14-hydroxyl-7,8-dihydro desmethylmorphine ketone purity is high and contain 14-hydroxyl-7, the composition of 8-dihydrocodeinone, the aminoacid sequence of wherein said demethylase:
(1) as shown in SEQ ID No:2, or
(2) be to SEQ ID No:2 disappearance, add and/or replace one or several amino-acid residue and the sequence of the reservation SEQ ID No:2 activity that obtains;
(C) 14-hydroxyl-7 in composition step (B) being obtained, 8-dihydro desmethylmorphine ketoalkylation becomes naloxone, obtains naloxone purity high also containing 14-hydroxyl-7, the composition of 8-dihydrocodeinone; With,
(D) be optionally further purified and/or composition that salt acidification step (C) obtains.
This is the method that the enzyme process of reported first participates in preparing naloxone, wherein used demethylase, its aminoacid sequence: (1) is as shown in SEQ ID No:2, or (2) are to SEQ ID No:2 disappearance, add and/or replace one or several amino-acid residue and the sequence of the reservation SEQ ID No:2 activity that obtains.
In this article, " optionally " has its lexical meaning, selects or do not select.For example, the method for first aspect present invention can select to comprise step (A), and the thebaine (Thebaine) of take is prepared naloxone as raw material; Also can select not comprise step (A), with 14-hydroxyl-7,8-dihydrocodeinone is that raw material is prepared naloxone.Conventionally preferably the former.
And for example, the method for first aspect present invention can select to comprise step (D); Also can select not comprise step (D), produce naloxone purity high also containing 14-hydroxyl-7, the composition of 8-dihydrocodeinone.The preferred the latter of the present invention, preferably the former, because the inventor finds, naloxone purity is high also containing 14-hydroxyl-7, the composition of 8-dihydrocodeinone can be directly as medicine material and patent medicine, even may be useful to patent medicine character, without expensive later stage purge process (remove a small amount of 14-hydroxyl-7 from naloxone, 8-dihydrocodeinone needs expensive chromatographic separation process).So the method for first aspect present invention can be that enzyme process is prepared high 14-hydroxyl-7, the method for the composition of 8-dihydrocodeinone of also containing of naloxone purity.
In this article, as without contrary indication, in composition, " purity " of composition and " content " can exchange use, all refer to this composition shared proportion in composition, and this area normalization method by HPLC just can calculate easily.Naloxone purity prepared by the method for first aspect present invention is high also containing 14-hydroxyl-7, in the composition of 8-dihydrocodeinone, naloxone purity is high, preferably in the method for first aspect present invention, in the composition obtaining in step (C), the purity of naloxone is greater than 95%, be preferably greater than 96%, more preferably greater than 97%, as be greater than 97.5%.
Because naloxone purity is high, 14-hydroxyl-7 in the composition obtaining in step (C), the content of 8-dihydrocodeinone is just low.Preferably in the method for first aspect present invention, in the composition obtaining in step (C), 14-hydroxyl-7, the content of 8-dihydrocodeinone is less than 5%, is preferably less than 4%, is more preferably less than 3%, as is less than 2.5%.14-hydroxyl-7, the content of 8-dihydrocodeinone cannot be avoided with enzyme process preparation, the statement of " containing 14-hydroxyl-7; 8-dihydrocodeinone " has shown 14-hydroxyl-7 in composition, the content of 8-dihydrocodeinone is not 0, for the purpose of clearer, 14-hydroxyl-7, the content lower limit of 8-dihydrocodeinone can be 0.3%.
Also preferred in the method for first aspect present invention, in step (A), thebaine is become 14-hydroxycodeine ketone by hydrogen peroxide oxidation in formic acid, and then 14-hydroxycodeine ketone is hydrogenated to 14-hydroxyl-7 by hydrogen, 8-dihydrocodeinone.Wherein preferably the catalyzer of hydrogen hydrogenation is Pd/C.In addition, preferably 14-hydroxycodeine ketone and/or 14-hydroxyl-7,8-dihydrocodeinone can precipitate extraction in basic solution, and more preferably wherein the pH of basic solution is 8.0～9.0, especially 8.1～8.5, as 8.2.
Preferably in the method for first aspect present invention, under the effect of demethylase, by 14-hydroxyl-7,8-dihydrocodeinone generates 14-hydroxyl-7 in acidity containing in the solution of halfcystine, 8-dihydro desmethylmorphine ketone purity is high also containing 14-hydroxyl-7, the composition of 8-dihydrocodeinone.Preferably wherein the pH value of acidity is 5.5～6.3, as 6.0.Preferably the temperature of demethylase reaction is 20～33 ℃ in addition, especially 25～30 ℃, as 28 ℃; And/or preferably the time of demethylase reaction is 1～10 hour, is preferably 3～8 hours, as 5 hours.For fear of the degrading activity of demethylase of the present invention, improve raw material availability, temperature of reaction can not be higher than 35 ℃.The composition that also preferred steps (B) obtains in addition can precipitate extraction in basic solution, and more preferably wherein the pH of basic solution is 8.0～9.0, and especially 8.3～8.3, as 8.5.
Like this, in the composition obtaining in step (B), although cannot remove 14-hydroxyl-7,8-dihydrocodeinone impurity, can make its content not form impact to final patent medicine, even may be useful.Preferably in the method for first aspect present invention, in the composition obtaining in step (B), 14-hydroxyl-7, the purity of 8-dihydro desmethylmorphine ketone is greater than 90%, is preferably greater than 92%, more preferably greater than 93%, as is greater than 93.5%.Correspondingly, preferably in the method for first aspect present invention, in the composition obtaining in step (B), 14-hydroxyl-7, the content of 8-dihydrocodeinone is less than 10%, is preferably less than 8%, is more preferably less than 7%, as is less than 6%.So preferably, in the method for first aspect present invention, step (B) does not comprise the further step of purifying of the composition that step (B) is obtained.The composition that so direct use step (B) obtains can further increase cost advantage.
Preferred in the method for first aspect present invention in addition, in step (C), 14-hydroxyl-7,8-dihydro desmethylmorphine ketone is alkylated into naloxone by bromopropylene.The composition that preferred steps (C) obtains can precipitate extraction in basic solution, and more preferably wherein the pH of basic solution is 8.5～9.5, and especially 8.8～9.3, as 9.0.
Preferred in the method for first aspect present invention in addition, in step (D), purifying is chromatography purification, preferably HPLC purifying; And/or salt acidifying is to add hydrochloric acid neutralization.
In second aspect, the invention provides the composition containing naloxone, it comprises naloxone and contains 14-hydroxyl-7,8-dihydrocodeinone.
Preferably, in the composition of second aspect present invention, naloxone purity is high, and in said composition, the purity of naloxone is greater than 95%, is preferably greater than 96%, more preferably greater than 97%, as is greater than 97.5%.Correspondingly, 14-hydroxyl-7, the content of 8-dihydrocodeinone is low, can be surplus, preferred 14-hydroxyl-7, the content of 8-dihydrocodeinone is less than 5%, is preferably less than 4%, is more preferably less than 3%, as is less than 2.5%.But, in the present invention, 14-hydroxyl-7, the content of 8-dihydrocodeinone is not 0, for the sake of clarity, and 14-hydroxyl-7, the content lower limit of 8-dihydrocodeinone can be 0.3%.
Preferably the composition of second aspect present invention is to be prepared by the method for first aspect present invention.Therefore, each preferred aspect in the method for preferred first aspect present invention.
Also the patent medicine effect of the composition of preferred second aspect present invention and naloxone are without remarkable difference.Wherein, patent medicine effect comprises pharmacodynamics and security effect.In this article, " without significantly difference " has the statistical implication of knowing, as p<0.01.In fact, according to the specific embodiment of the present invention, the patent medicine effect of the composition of second aspect present invention also may have advantage than existing naloxone, can replace existing naloxone patent medicine completely.So preferably the composition of second aspect present invention is pharmaceutical composition.
In the third aspect, the composition that the invention provides second aspect present invention is replacing naloxone (the especially Narlan of equivalent) to prepare the application in medicine, the application of the composition that the invention provides second aspect present invention in the medicine of preparing the disease that naloxone can treat.
The disease that naloxone can be treated comprises, poisoning disease, as acute heroin poisoning, acute alcoholism, Acute Nitrite Poisoning, organophosphate poisoning and/or ACMP; Cental system disease, as cerebral infarction (cerebral apoplexy), acute severe hematencephalon, the swelling of traumatic Diffuse brain, Patients with Severe Brain Injury and/or dizzy; Pediatric disease, as hypoxic ischemic encephalopathy of newborn, asphyxia neonatorum, primary premature breathlessness and/or infantile convulsion continue; And, hepatic disease, schizophrenia and/or severe myocardial ischemia etc.
In fourth aspect, the invention provides the authentication method of the composition of second aspect present invention, it comprises detection naloxone and 14-hydroxyl-7, the existence of 8-dihydrocodeinone.Because prior art adopts chemosynthesis; 14-hydroxyl-7 wherein; 8-dihydrocodeinone is added protecting group and 100% conversion when as intermediate product; and utilize fat-soluble qualitative difference to be easy to just can extract and remove 14-hydroxyl-7; 8-dihydrocodeinone; so report does not comprise 14-hydroxyl-7,8-dihydrocodeinone impurity in final Narlan product.Preferred detection can adopt HPLC to detect, and with naloxone and 14-hydroxyl-7, the standard substance of 8-dihydrocodeinone relatively determine whether to exist, thereby identify whether be the composition of second aspect present invention.
Aspect the 5th, the invention provides demethylase, its aminoacid sequence:
(1) as shown in SEQ ID No:2, or
(2) be to SEQ ID No:2 disappearance, add and/or replace one or several (be preferably no more than 7, more preferably no more than 5, as be no more than 3) amino-acid residue and the sequence of the reservation SEQ ID No:2 activity that obtains.
This endonuclease capable is with 14-hydroxyl-7, and the so complicated fused ring compound of 8-dihydrocodeinone is substrate, carries out efficiently demethylating reaction, can take off N-methyl and O-methyl.
Aspect the 6th, the invention provides the encoding gene (polynucleotide) of the demethylase of fifth aspect present invention.Those skilled in the art, by recombinant DNA technology, can prepare the misfolded proteins obtaining through disappearance, interpolation and/or substituted amino acid residue.In the specific embodiment of the present invention, demethylase is nucleotide sequence coded by as shown in SEQ ID No:1.This demethylase is to 14-hydroxyl-7,8-dihydrocodeinone and 14-hydroxyl-7, and 8-dihydro desmethylmorphine ketone has certain degrading activity, especially when temperature is during higher than 35 ℃.So in order to improve raw material availability, the temperature of reaction of this enzyme can not be higher than 35 ℃.In addition, in order to prevent continuing of degraded, the reaction times can not be long, is conventionally less than 12 hours, and therefore reaction can not completely, can contain a small amount of 14-hydroxyl-7,8-dihydrocodeinone impurity.
Aspect the 7th, the invention provides carrier, it comprises the encoding gene of sixth aspect present invention.Preferred vector is expression vector, if the expression vector of expressing in intestinal bacteria or yeast.
In eight aspect, the invention provides cell, the encoding gene that it comprises sixth aspect present invention, or transform or transfection with the carrier of seventh aspect present invention.By recombinant DNA technology, polynucleotide can directly be imported into, such as utilizing the transfered cells such as microsome, particle gun; Also can indirectly be imported into, for example can be by being structured in transfered cell on plasmid vector.The described polynucleotide that import can be incorporated on the genome of cell and express, and expression also can dissociate.Preferred cell is secreting, expressing cell, as the yeast of secreting, expressing.
Aspect the 9th, the invention provides the method for fermentative production demethylase, it comprises the cell of under fermentation conditions cultivating eighth aspect present invention, isolates the demethylase of fifth aspect present invention from culture.If use secreting, expressing cell, can simplify sepn process, as remove by filter cell and retain supernatant liquor, wherein preferably use 0.22 μ m filter membrane to filter.The supernatant liquor that separation obtains can be directly used in the method for first aspect present invention, also can further purify and/or concentrate.
The present invention has following beneficial effect: in preparation method of the present invention, at least demethylating reaction step is easy, reaction conditions is gentle, reagent and residual substantially harmless; Although the Narlan composition that the present invention obtains contains 14-hydroxyl-7 that more difficult purifying is removed, 8-dihydrocodeinone impurity, does not affect patent medicine effect, even can have some superiority, can substitute existing Narlan completely and use; Separated owing to having removed impurity from, can further reduce costs, make patent medicine advantage more obvious.
For the ease of understanding, below will to the present invention, be described in detail by specific embodiment.It needs to be noted, these descriptions are only exemplary descriptions, do not form limitation of the scope of the invention.According to the discussion of this specification sheets, many variations of the present invention, change are all apparent concerning one of ordinary skill in the art.In addition, the present invention has quoted open source literature, and these documents are in order more clearly to describe the present invention, and their full text content is all included in and carried out reference herein, and the full text that just looks like them has repeated in this article and clearly recorded the same.
Embodiment
Further illustrate by the following examples content of the present invention.As do not specialize, the conventional means that in embodiment, technique means used is well known to those skilled in the art and commercially available common instrument, reagent, can be referring to the references such as manufacturers instruction of the test handbooks such as < < organic synthesis > > and < < molecular cloning experiment guide > > and corresponding instrument and reagent.
The expression of embodiment 1 demethylase gene
According to our platform technology, designed new enzyme gene, entrust the synthetic codon of Sangon Biotech (Shanghai) Co., Ltd. to express the demethylase gene of optimizing, its nucleotide sequence is as shown in the SEQ ID No:1 of sequence table, and the aminoacid sequence of this genes encoding is as shown in SEQ ID No:2.Then, according to < < molecular cloning experiment guide > >, build the yeast of this enzyme of secreting, expressing, take synthetic gene as masterplate, with primer 1(SEQ ID No:3, introduced EcoR I restriction enzyme site) and primer 2 (SEQ ID No:4, introduced Not I restriction enzyme site) after pcr amplification with EcoR I and Not I double digestion, and be connected with T4DNA ligase enzyme with pPIC3.5 plasmid through these two endonuclease digestions (can purchased from Invitrogen company), be transformed in bacillus coli DH 5 alpha.Choose positive colony, extract plasmid wherein, after sequence verification is correct, positive plasmid, with after Sal I linearization for enzyme restriction, is transformed into pichia yeast GS115 strain by electrotransformation, containing on the flat board of G418, choosing positive Yeast transformant.
Above-mentioned positive Yeast transformant is inoculated into 50ml BMGY liquid nutrient medium, and (formula is: in every 100mM potassium phosphate buffer (pH6.0), comprise, 1% yeast extract, 2% peptone, yeast nitrogenous base 1.34%, vitamin H 0.0004%, glucose 2%, glycerine 1%), in, in 32 ℃, with 180rpm shaking table, be cultured to OD600 and reach 4.0.Above-mentioned culture is transferred in 1L BMGY liquid nutrient medium, in 31 ℃, with 180rpm shaking table, cultivate 16 hours, add 5ml methyl alcohol, then continuing at 30 ℃ cultivates 10 days with 180rpm shaking table, within every 24 hours during this time, add 5ml methyl alcohol, ventilation is controlled dissolved oxygen (DO) and is greater than 22%, and to control pH be that 5.8(regulates with ammoniacal liquor).After cultivation completes, with 0.22 μ m membrane filtration and retain supernatant liquor, this supernatant liquor detects the band that substantially only has obvious 40kDa through SDS-PAGE, shows to ferment to obtain this demethylase.Can will after the direct lyophilize of supernatant liquor, in 4 ℃ of refrigerators, preserve.
The production of embodiment 2 naloxones
(1) 14-hydroxyl-7, the chemosynthesis of 8-dihydrocodeinone
Substantially according to prior art hydrogen oxide, be combined to, concrete improve as follows: take in the anhydrous formic acid that 50g thebaine joins 100mL ice bath, after stirring and dissolving, under condition of ice bath, drip 30%(V/V) superoxol 22mL, then stir 1 hour, be warming up to afterwards 37 ℃ of room temperatures and continue to stir 2.5 hours.Then, to reaction solution, adding 60mL acetone and 60mL water, then drip 20%(W/W) sodium hydroxide solution is until pH reaches 8.2, dropwises latter static 0.5 hour, can separate out precipitation during this time, after filtering, be dried to obtain white powder (14-hydroxycodeine ketone) 44.3g.Above-mentioned white powder is dissolved in to 200mL10%(W/W) in acetic acid solution, add Pd/C catalyzer 4g, in 20 ℃ of pressure with 4MPa, pass into hydrogen and constantly stir, react thus 3 hours.Then drip 20%(W/W) sodium hydroxide solution is until pH reaches 8.2, dropwises latter static 0.5 hour, during can separate out precipitation, after filtering, the dry white powder 42.8g of obtaining, is oxidized hydrogenation and has obtained 14-hydroxyl-7,8-dihydrocodeinone.
(2) 14-hydroxyl-7, the enzyme process preparation of 8-dihydro desmethylmorphine ketone
Get 14-hydroxyl-7 of above-mentioned preparation, 8-dihydrocodeinone 10g, add 50mL water, and then drip Glacial acetic acid until pH reaches 6.0 under the condition stirring, then the demethylase lyophilized powder 350mg and the halfcystine 9.6g that add embodiment 1 preparation, in 28 ℃ (can not higher than 35 ℃) with 50rpm shaking table oscillatory reaction 5 hours.Then dripping 20%(W/W) sodium hydroxide solution is until pH reaches 8.5, dropwise latter static 0.5 hour, can separate out precipitation during this time, after filtering, be dried to obtain off-white powder 7.6g, through HPLC, identify (area normalization method), 14-hydroxyl-7 wherein, 8-dihydro desmethylmorphine ketone purity is 93.6%, 14-hydroxyl-7,8-dihydrocodeinone content is 5.7%.Then drip 20%(V/V) ammoniacal liquor is until pH reaches 8.2, dropwises latter static 0.5 hour, during can separate out precipitation
(3) chemosynthesis of naloxone
Substantially synthetic according to prior art alkanisation, concrete improvement is as follows: without purification, the off-white powder 5g that directly gets above-mentioned preparation mixes with 400mL dehydrated alcohol, then adds successively sodium bicarbonate 4.9g and bromopropylene (BrCH
2cH=CH
2) 4.3mL, be heated to 90 ℃ of back flow reaction 5 hours, while being evaporated to 20mL, add 20mL water dissolution.Then drip 20%(W/W) sodium hydroxide solution is until pH reaches 9, dropwises latter static 0.5 hour, during can separate out precipitation, recrystallization soluble in water after filtration drying, obtains white powder 4.7g, is naloxone composition of the present invention.Through HPLC, identify (area normalization method), in said composition, naloxone purity is 97.7%, 14-hydroxyl-7, and 8-dihydrocodeinone content is 2.0%.To after the pure naloxone of HPLC separation and hydrochloric acid salify, carry out hydrogen nuclear magnetic resonance analysis, 1HNMR (d6-DMSO) result is as follows: δ 9.50 (s1H), 9.39 (s1H), 6.84 (s1H), 6.68 (d1H), 6.60 (d1H), 5.94 (m1H), 5.61,5.61 (dd2H), 5.02 (s1H), 3.94,3.79 (m2H), 3.65 (s1H), 3.39 (t2H), 3.39 (2H), 3.31,3.96,2.67 (m4H), 2.11,1.99 (dd2H), 1.48 (m2H), consistent with bibliographical information.
Drug effect and the safety testing of embodiment 3 naloxone compositions
The naloxone composition of Experimental agents: embodiment 2 preparations, without expensive purification, directly uses in hydrochloric acid and rear administration.
Control drug: naloxone hydrochloride injection (Yiqiao (Hunan) Pharmaceutical Co., Ltd.).
Experimental technique: BALB/c mouse (body weight 18-22g, male and female half and half) is divided into following 6 groups at random, every group of 10 animals: 1) blank group (administration distilled water); 2) model group (gastric infusion 50% ethanolic soln 1mL); ; 3) control drug high dose group (drug administration by injection is in naloxone 0.5mg/kg+ gastric infusion 50% ethanolic soln 1mL); 4) control drug low dose group (drug administration by injection is in naloxone 0.1mg/kg days+gastric infusion 50% ethanolic soln 1mL); 5) Experimental agents high dose group (drug administration by injection with naloxone and 14-hydroxyl-7,8-dihydrocodeinone total amount meter 0.5mg/kg+ gastric infusion 50% ethanolic soln 1mL); 6) Experimental agents low dose group (drug administration by injection with naloxone and 14-hydroxyl-7,0.1mg/kg days+gastric infusion of 8-dihydrocodeinone total amount meter 50% ethanolic soln 1mL).Below respectively organize administration every day 1 time, continuous 30 days.At the 30th day, mouse administration, after l2 hour, is weighed mouse, put to death, and take a blood sample and get liver organization.After separation of serum, use gpt detection kit, glutamic-oxal(o)acetic transaminase detection kit not to measure gpt (SGPT) activity and glutamic-oxal(o)acetic transaminase (SGOT) activity; Meanwhile, get rat and get liver, through 10% formalin solution, fix, after dehydration, paraffin embedding, film-making (4 μ m are thick), HE dyeing, by pathology professional, under opticmicroscope, check and have or not pathology and carry out pathology scoring.
Pharmacodynamic result is as shown in table 1 below, and in model group, the serum glutamic pyruvic transminase of mouse and glutamic-oxal(o)acetic transaminase level all significantly raise; Use naloxone composition of the present invention and commercially available control drug, can significance reduce gpt and the glutamic-oxal(o)acetic transaminase level of mouse, especially in the situation that high dosage is used, the effect of naloxone composition of the present invention is also slightly better than commercially available control drug.Meanwhile, tissue slice microscopy shows, in model group, liver tissue lesions's main manifestations is hepatocellular degeneration, occurs spotty necrosis or focal necrosis in liver, occurs that liver internal jugular vein is scorching, the visible a small amount of cell infiltration in liver and portal area and fibroblast proliferation; Use naloxone composition of the present invention and commercially available control drug, can significance reduce liver tissue lesions's degree of mouse, same in the situation that high dosage is used, the effect of naloxone composition of the present invention is also slightly better than commercially available control drug.Expectation is 14-hydroxyl-7 of certain content, and the treatment of 8-dihydrocodeinone Ye Dui liver tissue lesions is favourable.
The pharmacodynamic experiment result of table 1 naloxone composition of the present invention
| Group | SGPT（IU） | SGOT（IU） | Pathology scoring |
| 1 | 38±17 | 92±11 | 0 |
| 2 | 186±22 | 143±15 | 0.95±0.25 |
| 3 | 99±16 ** | 81±7 ** | 0.15±0.18 ** |
| 4 | 119±12 ** | 82±25 ** | 0.28±0.20 ** |
| 5 | 83±25 ** | 78±18 ** | 0.08±0.07 ** |
| 6 | 117±9 ** | 85±20 ** | 0.26±0.23 ** |
*expression is with respect to model group, p<0.01.
In addition BALB/c mouse is carried out to toxicity research, result shows, naloxone composition of the present invention is 112mg/kg to the LD50 of injected in mice, also higher than the LD50(107mg/kg of control drug), expectation and wherein 14-hydroxyl-7 of doses, 8-dihydrocodeinone is relevant.
Claims (10)
1. enzyme process is prepared the method for naloxone, and it comprises,
(A) optionally thebaine hydrogen oxide is changed into 14-hydroxyl-7,8-dihydrocodeinone;
(B) under the effect of demethylase, by 14-hydroxyl-7,8-paracodin ketogenesis 14-hydroxyl-7,8-dihydro desmethylmorphine ketone purity is high and contain 14-hydroxyl-7, the composition of 8-dihydrocodeinone, the aminoacid sequence of wherein said demethylase:
(1) as shown in SEQ ID No:2, or
(2) be to SEQ ID No:2 disappearance, add and/or replace one or several amino-acid residue and the sequence of the reservation SEQ ID No:2 activity that obtains;
(C) 14-hydroxyl-7 in composition step (B) being obtained, 8-dihydro desmethylmorphine ketoalkylation becomes naloxone, obtains naloxone purity high also containing 14-hydroxyl-7, the composition of 8-dihydrocodeinone; With,
(D) composition that optional (but not preferred) is further purified and/or salt acidification step (C) obtains.
2. method claimed in claim 1, wherein, in the composition obtaining in step (C), the purity of naloxone is greater than 95%, is preferably greater than 96%, more preferably greater than 97%, as is greater than 97.5%; Or, in the composition obtaining in step (C), 14-hydroxyl-7, the content of 8-dihydrocodeinone is less than 5%, is preferably less than 4%, is more preferably less than 3%, as is less than 2.5%; Or, in step (C), 14-hydroxyl-7,8-dihydro desmethylmorphine ketone is alkylated into naloxone by bromopropylene.
3. method claimed in claim 1, wherein, in step (A), thebaine is become 14-hydroxycodeine ketone by hydrogen peroxide oxidation in formic acid, and then 14-hydroxycodeine ketone is hydrogenated to 14-hydroxyl-7 by hydrogen, 8-dihydrocodeinone.
4. method claimed in claim 1, wherein, in the composition obtaining in step (B), 14-hydroxyl-7, the purity of 8-dihydro desmethylmorphine ketone is greater than 90%, is preferably greater than 92%, more preferably greater than 93%, as is greater than 93.5%; Or, in the composition obtaining in step (B), 14-hydroxyl-7, the content of 8-dihydrocodeinone is less than 10%, is preferably less than 8%, is more preferably less than 7%, as is less than 6%; Or step (B) does not comprise the further step of purifying of the composition that step (B) is obtained.
5. containing the composition of naloxone, it comprises naloxone and contains 14-hydroxyl-7,8-dihydrocodeinone, and wherein the purity of naloxone is greater than 95%, is preferably greater than 96%, more preferably greater than 97%, as is greater than 97.5%; Or, 14-hydroxyl-7 wherein, the content of 8-dihydrocodeinone is less than 5%, is preferably less than 4%, is more preferably less than 3%, as is less than 2.5%.
6. composition claimed in claim 5, preferably it is to be prepared by arbitrary described method of claim 1～4.
7. the composition described in claim 5 or 6, its patent medicine effect and naloxone are without remarkable difference.
The arbitrary described composition of claim 5～7 prepare the disease that naloxone can treat (be selected from: poisoning disease, as acute heroin poisoning, acute alcoholism, Acute Nitrite Poisoning, organophosphate poisoning and/or ACMP; Cental system disease, as cerebral infarction (cerebral apoplexy), acute severe hematencephalon, the swelling of traumatic Diffuse brain, Patients with Severe Brain Injury and/or dizzy; Pediatric disease, as hypoxic ischemic encephalopathy of newborn, asphyxia neonatorum, primary premature breathlessness and/or infantile convulsion continue; And, hepatic disease, schizophrenia and/or severe myocardial ischemia) medicine in application.
9. the authentication method of the arbitrary described composition of claim 5～7, it comprises and detects naloxone and 14-hydroxyl-7, the existence of 8-dihydrocodeinone.
10. demethylase, its encoding gene, carrier, cell or preparation method, the aminoacid sequence of described demethylase:
(1) as shown in SEQ ID No:2, or
(2) be to SEQ ID No:2 disappearance, add and/or replace one or several amino-acid residue and the sequence of the reservation SEQ ID No:2 activity that obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310711466.8A CN103695497B (en) | 2013-12-20 | 2013-12-20 | Enzymatic preparation of naloxone and pharmaceutical composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310711466.8A CN103695497B (en) | 2013-12-20 | 2013-12-20 | Enzymatic preparation of naloxone and pharmaceutical composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103695497A true CN103695497A (en) | 2014-04-02 |
| CN103695497B CN103695497B (en) | 2014-09-17 |
Family
ID=50357160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310711466.8A Expired - Fee Related CN103695497B (en) | 2013-12-20 | 2013-12-20 | Enzymatic preparation of naloxone and pharmaceutical composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103695497B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110114457A (en) * | 2016-10-18 | 2019-08-09 | 安思雅公司 | Generate the method for removing first opiates and NAL- opiates benzyl isoquinoline alkaloid |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101036650A (en) * | 2006-03-16 | 2007-09-19 | 薛京 | Naloxone hydrochloride dropping pills |
| CN101370503A (en) * | 2006-01-19 | 2009-02-18 | 福奴克斯股份公司 | Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts |
| CN101437517A (en) * | 2006-04-14 | 2009-05-20 | 夏尔有限责任公司 | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
| CN101513407A (en) * | 2009-04-03 | 2009-08-26 | 单风平 | Application of naloxone and composition thereof in preparing drug for treating cancer |
| CN101955484A (en) * | 2010-06-26 | 2011-01-26 | 甘肃普安制药有限公司 | Method for synthesizing naloxone or naltrexone |
-
2013
- 2013-12-20 CN CN201310711466.8A patent/CN103695497B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101370503A (en) * | 2006-01-19 | 2009-02-18 | 福奴克斯股份公司 | Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts |
| CN101036650A (en) * | 2006-03-16 | 2007-09-19 | 薛京 | Naloxone hydrochloride dropping pills |
| CN101437517A (en) * | 2006-04-14 | 2009-05-20 | 夏尔有限责任公司 | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
| CN101513407A (en) * | 2009-04-03 | 2009-08-26 | 单风平 | Application of naloxone and composition thereof in preparing drug for treating cancer |
| CN101955484A (en) * | 2010-06-26 | 2011-01-26 | 甘肃普安制药有限公司 | Method for synthesizing naloxone or naltrexone |
Non-Patent Citations (3)
| Title |
|---|
| 冯智英等: "盐酸吗啡对肠道运动的离体与在体作用及机制研究", 《浙江大学学报(医学版)》, no. 03, 15 May 2008 (2008-05-15) * |
| 卓杰等: "脑室注射纳洛酮对大鼠脑缺血再灌注损伤的保护作用", 《河北医药》, no. 02, 26 February 2004 (2004-02-26) * |
| 陆以信等: "脑啡肽的放射免疫测定", 《生物化学与生物物理进展》, no. 02, 25 April 1980 (1980-04-25) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110114457A (en) * | 2016-10-18 | 2019-08-09 | 安思雅公司 | Generate the method for removing first opiates and NAL- opiates benzyl isoquinoline alkaloid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103695497B (en) | 2014-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102038241B1 (en) | Novel low molecular weight cationic lipids for oligonucleotide delivery | |
| CN103908468A (en) | Application of cyclic dinucleotide cGAMP in preparing anti-tumor medicaments | |
| CN104450746A (en) | Method for fixed-point introduction of non-natural amino acid to protein | |
| CN103288808B (en) | A kind of Ah method is for the preparation method of Buddhist nun | |
| CN108947949B (en) | Anxiolytic deuterated compounds and medical application thereof | |
| CN103695497B (en) | Enzymatic preparation of naloxone and pharmaceutical composition thereof | |
| EP2743258B1 (en) | Method for purifying levo-oxiracetam | |
| CN108101910B (en) | N-substituted pyrazolo [3,4-d ] pyrimidone compound and preparation method and application thereof | |
| CN101270102A (en) | Process for synthesizing parthenolide derivative and uses thereof | |
| WO2021071984A1 (en) | Compounds for modulating splicing | |
| CN106631957A (en) | Antitumor compound targeting FAP-alpha enzyme and preparation method and application thereof | |
| CN103254156B (en) | Ah method is for the preparation method of Buddhist nun's intermediate | |
| CN109111386A (en) | The synthetic method of L- prolineamide | |
| CN102180810A (en) | Preparation method of 4-hydroxyphenylacetonitrile | |
| CN106883185B (en) | Preparation method of 4-chloro-2-trifluoromethylpyrimidine | |
| CN104557623A (en) | Preparation method of 4-amino-6-(trichloroethenyl)-1, 3-benzene disulfonamide | |
| CN112574179B (en) | DNA-PK inhibitors | |
| CN111171017B (en) | Pyrimidine-based derivatives, their preparation and use | |
| CN115873018B (en) | Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof | |
| CN103242244B (en) | Canertinib preparation method | |
| CN111533726B (en) | Preparation method of hematoxylin derivative, product prepared by preparation method and application of product | |
| CN102895233A (en) | Application of benzoazepine compounds in preparation of drugs for prevention or treatment of epilepsy | |
| WO2021052470A1 (en) | Nucleic acid molecule for treating immune thrombocytopenia and application thereof | |
| CN109280046B (en) | Benzimidazole derivative, preparation method thereof and application thereof in medicine | |
| CN101481338B (en) | Synthesizing method and use of vanadium taurate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180223 Address after: 610000, No. 88, No. 88, No. 12, No. 88, South Road, Chengdu Hi-tech Zone, Chengdu high tech Zone Patentee after: Shumeiqi Chengdu Biotechnology Co.,Ltd. Address before: 300457 Tianjin biological medicine Joint Research Institute, No. 220 Dongting Road, Binhai New Area, Tianjin, N1302 Patentee before: TIANJIN QIFANG MEDICAL TECHNOLOGY Co.,Ltd. |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: GUANGZHOU WEISIBAO PHARMACEUTICAL Co.,Ltd. Document name: Notification of Approving Refund |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140917 Termination date: 20211220 |